Sarepta Therapeutics,
Inc. SRPT, a developer of innovative RNA-based
therapeutics, today announced it will hold a conference call at 8:00
a.m. EDT (5:00 a.m. PDT) on Wednesday, July 24, 2013, to provide a
regulatory update for eteplirsen, its lead product candidate for the
treatment of Duchenne muscular dystrophy (DMD).
The conference call may be accessed by dialing 800.446.2782 for
domestic callers and 847.413.3235 for international callers. The
passcode for the call is 35357086. Please specify to the operator
that you would like to join the "Sarepta Therapeutics Regulatory
Update Call." The conference call will be webcast live under the
events section of Sarepta's website at www.sarepta.com and will be
archived there following the call for 90 days. Please connect to
Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be
necessary.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in